GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat
Episode S26 · Ep 380 55 min 15s

GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat

Featuring an interview with Prof Rakesh Popat, including the following topics:

  • Overview of GPRC5D and its clinical significance (0:00)
  • Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab (2:30)
  • Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy (6:25)
  • Key findings from the Phase III MonumenTAL-3 study (11:49)
  • Selection factors for GPRC5D- and BCMA-directed therapies (15:16)
  • Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond (18:30)
  • Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM (20:47)
  • Ramantamig and other GPRC5D-targeted approaches (25:32)
  • Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies (28:42)
  • Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response (38:27)
  • Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant (45:18)
  • Guidance on sequencing BCMA- and GPRC5D-directed therapies (47:35)
  • Importance of tumor debulking; access to arlo-cel (52:27)

CME information and select publications

Community discussion